TrialJournal for immunotherapy of cancer2023

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Wenwen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.